Toll Free: 1-888-928-9744

Critical Limb Ischemia - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 150 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Critical Limb Ischemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H1 2016', provides an overview of the Critical Limb Ischemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
- The report reviews pipeline therapeutics for Critical Limb Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Critical Limb Ischemia therapeutics and enlists all their major and minor projects
- The report assesses Critical Limb Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Critical Limb Ischemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Critical Limb Ischemia Overview 10 Therapeutics Development 11 Pipeline Products for Critical Limb Ischemia - Overview 11 Pipeline Products for Critical Limb Ischemia - Comparative Analysis 12 Critical Limb Ischemia - Therapeutics under Development by Companies 13 Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 15 Critical Limb Ischemia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Critical Limb Ischemia - Products under Development by Companies 19 Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21 Critical Limb Ischemia - Companies Involved in Therapeutics Development 22 AnGes MG, Inc. 22 Apceth GmbH & Co. KG 23 Athersys, Inc. 24 Caladrius Biosciences, Inc. 25 Cynata Therapeutics Limited 26 Hemostemix Ltd 27 Histocell S.L. 28 ID Pharma Co., Ltd. 29 IntelliCell BioSciences Inc. 30 Juventas Therapeutics, Inc. 31 Kasiak Research Private Limited 32 Kowa Company, Ltd. 33 Multi Gene Vascular Systems Ltd 34 Pharmicell Co., Ltd. 35 Pluristem Therapeutics Inc. 36 ReNeuron Group Plc 37 Stempeutics Research Private Limited 38 Targazyme, Inc. 39 TikoMed AB 40 U.S. Stem Cell, Inc. 41 Vericel Corporation 42 ViroMed Co., Ltd. 43 Critical Limb Ischemia - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 ACP-01 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AdipoCell - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Alecmestencel-T - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ASCT-01 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 beperminogene perplasmid - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Cellgram-CLI - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CLBS-12 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DVC-10101 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Gene Therapy for Critical Limb Ischemia - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 HC-016 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 ixmyelocel-T - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 JVS-100 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 MultiGeneAngio - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PF-05285401 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pitavastatin NP - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PLX-PAD - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Refacell-CLI - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Rejuveinix - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 ReN-009 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Stem Cell therapy for CNS, CVS, Dermatological, Immunological and Metabolic Disorders - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Stempeucel - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 TM-700 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 TXA-302 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 TZ-101 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 VM-202 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Critical Limb Ischemia - Recent Pipeline Updates 107 Critical Limb Ischemia - Dormant Projects 140 Critical Limb Ischemia - Discontinued Products 142 Critical Limb Ischemia - Product Development Milestones 143 Featured News & Press Releases 143 Apr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los Angeles 143 Apr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia 143 Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 144 Dec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States 145 Dec 21, 2015: Pluristem Reaches Agreement with Japan's PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated Pathway 145 Oct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the Mesa 146 Sep 14, 2015: Hemostemix Executes Strategic Alliance with Hemostemix Asia for Expansion of Phase-2 Clinical Trial to Taiwan 147 Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications 147 Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia 148 Aug 12, 2015: Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials 148 Appendix 149 Methodology 149 Coverage 149 Secondary Research 149 Primary Research 149 Expert Panel Validation 149 Contact Us 149 Disclaimer 150
List of Tables
Number of Products under Development for Critical Limb Ischemia, H1 2016 11 Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H1 2016 22 Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H1 2016 23 Critical Limb Ischemia - Pipeline by Athersys, Inc., H1 2016 24 Critical Limb Ischemia - Pipeline by Caladrius Biosciences, Inc. , H1 2016 25 Critical Limb Ischemia - Pipeline by Cynata Therapeutics Limited, H1 2016 26 Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H1 2016 27 Critical Limb Ischemia - Pipeline by Histocell S.L., H1 2016 28 Critical Limb Ischemia - Pipeline by ID Pharma Co., Ltd., H1 2016 29 Critical Limb Ischemia - Pipeline by IntelliCell BioSciences Inc., H1 2016 30 Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H1 2016 31 Critical Limb Ischemia - Pipeline by Kasiak Research Private Limited, H1 2016 32 Critical Limb Ischemia - Pipeline by Kowa Company, Ltd., H1 2016 33 Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H1 2016 34 Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H1 2016 35 Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H1 2016 36 Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H1 2016 37 Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H1 2016 38 Critical Limb Ischemia - Pipeline by Targazyme, Inc., H1 2016 39 Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2016 40 Critical Limb Ischemia - Pipeline by U.S. Stem Cell, Inc., H1 2016 41 Critical Limb Ischemia - Pipeline by Vericel Corporation, H1 2016 42 Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H1 2016 43 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H1 2016 107 Critical Limb Ischemia - Dormant Projects, H1 2016 140 Critical Limb Ischemia - Dormant Projects (Contd..1), H1 2016 141 Critical Limb Ischemia - Discontinued Products, H1 2016 142


List of Figures
Number of Products under Development for Critical Limb Ischemia, H1 2016 11 Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Targets, H1 2016 45 Number of Products by Stage and Targets, H1 2016 45 Number of Products by Mechanism of Actions, H1 2016 47 Number of Products by Stage and Mechanism of Actions, H1 2016 47 Number of Products by Top 10 Routes of Administration, H1 2016 49 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 49 Number of Products by Molecule Types, H1 2016 51 Number of Products by Stage and Top 10 Molecule Types, H1 2016 51

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify